Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 3;26(10):1867–1875. doi: 10.1093/neuonc/noae108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Patients with truly unmethylated MGMTp do not benefit from TMZ treatment. The OS of truly MGMTp unmethylated patients, split by treatment arm, is illustrated by Kaplan–Meier plots for the trial populations. (A) In the Nordic/NOA8 population, a significant difference was observed between TMZ treatment and RT (P = .0381). Shorter survival was observed for patients treated with TMZ. (B) The comparison of RT versus RT/TMZ→TMZ in the truly MGMTp unmethylated patients of the CE.6 trial showed no OS difference between treatments (P = .1980).